RMC Pharmaceutical Solutions has been acquired by Syner-G Biopharma Group, a Portfolio Company of Riverside Partners, to expand regulatory compliance solutions.
Increasing regulatory pressure combined with escalating demand for faster drug development is expected to drive the market for pharmaceutical regulatory compliance services to nearly $15 billion by 2028. Within this growing market is Chemistry, Manufacturing and Control (CMC) and regulatory compliance services, which ensure that pharmaceutical companies and CDMOs comply with FDA regulations throughout the various stages of drug development.
RMC Pharmaceutical Solutions (RMC) is a leading provider of expert technical services focused on solving CMC issues in the biotechnology and pharmaceutical industry. RMC provides a diverse range of technical and consulting services including process, analytical and formulation development, quality control and assurance, GLP/GMP manufacturing of API and drug product, and packaging/distribution. The company’s service offerings were the ideal strategic complement to enhance Syner-G’s existing suite of comprehensive CMC solutions.
Crosstree acted as exclusive financial advisor to RMC in its acquisition by Syner-G through:
- Leveraging market expertise to evaluate post-transaction synergies and complementary capabilities of potential strategic partners
- Developing and articulating a compelling narrative for potential buyers
- Evaluating a broad slate of potential strategic and financial partners to help ensure the right fit for all stakeholders